Navigation Links
Boston Scientific Announces Results For Second Quarter Ended June 30, 2013
Date:7/25/2013

oston Scientific.  "As we continue to expand our portfolio, our team is inspired to deliver meaningful innovation to more patients globally."Worldwide sales for the second quarter: Three Months EndedJune 30,% Changein millions20132012As Reported BasisLess: Impact of Foreign CurrencyConstant Currency BasisInterventional Cardiology

$

520$

549(5)%

$

(15)(2)%

(3)%Peripheral Interventions

1991962%

(6)(3)%

5%Cardiovascular719745(4)%(21)(3)%(1)%Cardiac Rhythm Management

475488(3)%

(4)(1)%

(2)%Electrophysiology

3637(3)%

(1)(1)%

(2)%Rhythm Management511525(3)%(5)(1)%(2)%Endoscopy

3253115%

(11)(3)%

8%Urology/Women's Health

124126(1)%

(3)(2)%

1%Neuromodulation

1119121%

10%

21%MedSurg5605286%(13)(3)%9%Subtotal Core Businesses1,7901,7980%(39)(2)%2%Divested Businesses

1930(36)%

12%

(38)%Worldwide Net Sales$1,809$1,828(1)%$(38)(2)%1%Growth rates are based on actual, non-rounded amounts and may not recalculate precisely.

 Sales growth rates that exclude the impact of changes in foreign currency exchange rates are not prepared in accordance with U.S. GAAP.  An explanation of the company's use of these non-GAAP financial measures is included in the exhibits attached to this news release.

  

On a consolidated GAAP basis, net income for the second quarter of 2013 was $130 million, or earnings of $0.10 per share.  These results included an intangible asset impairment charge, acquisition- and divestiture-related net credits, restructuring-related charges, and amortization expense, of $117 million (after-tax) or $0.08 per share.  Adjusted net income for the second quarter of 2013, excluding these net charges, was $247 million, or $0.18 per share.

On a consolidated GA
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related biology technology :

1. American Laboratory Trading Continues Steady Growth with Expansion in Boston
2. Affordable Scrum Training in Boston,MA by Conscires Agile Practices
3. Formedix CEO Invited to Speak at OpenClinica Global Conference in Boston
4. The 2013 Bioprocessing Summit to Bring Together International Leaders to Discuss Today's Bioprocess Issues From Cell Line Selection to Manufacturing in Boston, MA
5. Verified Clinical Trials (VCT) Will Co-Present With SAFE-BioPharma At Bio-IT World April 10th In Boston, MA Exploring Identity Management In eClinical Trials
6. Boston Heart Diagnostics Awarded $450,000 in Tax Incentives from the Massachusetts Life Sciences Center
7. Local Leaders Convene in Boston to Share Industry Best Practices in Second “Business of Big Data” Summit
8. R&D, Innovation Key to Success - Research Report on Varian Medical Systems, Inc., Boston Scientific Corporation, Stryker Corporation, St. Jude Medical, Inc., and Thermo Fischer Scientific Inc.
9. Boston College researchers unique nanostructure produces novel plasmonic halos
10. Boston Scientific to Webcast Conference Call Discussing Fourth Quarter and Full Year 2012 Financial Results on January 29th
11. Shire and Boston Childrens Hospital Enter Into Broad Research Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... Charlotte, NC (PRWEB) October 24, 2014 ... high intensity focused ultrasound (HIFU) technology, announced that ... Carol, M.D. as Chief Executive Officer, President and ... new role Dr. Carol will take-on expanded responsibilities ... HIFU technology, as well as overseeing commercialization, manufacturing ...
(Date:10/25/2014)... JERUSALEM , October 24, 2014 ... a clinical-stage pharmaceutical company focused on the development of ... CEO, Nadav Kidron will present at FireRock ... ,FireRock Capital,s Annual Micro-Cap Conference ,Date: Tuesday, October 28, ... Building, New York City , ...
(Date:10/25/2014)... 2014 Investor-Edge has initiated coverage ... CYTR ), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX ... Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM ), and ... companies can be accessed at: http://investor-edge.com/register . ... ended on a positive note as the Dow Jones ...
(Date:10/22/2014)... 22, 2014 New test innovations will be ... diagnostic (IVD) test industry, especially as companies struggle with ... listed more than 25 testing innovations in important disease ... of IVD products. Kalorama details the new approaches its biennial ... for In Vitro Diagnostic Tests , 9th Edition ...
Breaking Biology Technology:SonaCare Medical Board of Directors Appoints Dr. Mark Carol as CEO and President 2SonaCare Medical Board of Directors Appoints Dr. Mark Carol as CEO and President 3Oramed to Present at the FireRock Annual Micro-Cap Conference 2Oramed to Present at the FireRock Annual Micro-Cap Conference 3Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 2Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 3Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 4Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 5Report: Radical New IVD Test Approaches Key To Growth 2Report: Radical New IVD Test Approaches Key To Growth 3
... Inc. (Nasdaq:,BIOD) today reported financial results for its second quarter ... $9.6 million or $0.43 per share., "We remain on ... and Chairman of Biodel. "The last patient visits for,both pivotal ... We,expect to announce top line data late in the third ...
... Pennsylvania and OXFORD, England, May 9 ,EUSA Pharma ... oncology, pain control and critical care, today announced ... following the,approval of Cytogen,s shareholders at a special ... of the acquisition agreement, Cytogen shareholders will,receive $0.62 ...
... Pharmaceuticals, Inc.,(Nasdaq: ARNA ) announced today that the ... 2008 Healthcare Conference on May 14, 2008 at 5:20 ... Seasons Hotel in Las,Vegas, Nevada. Dominic P. Behan, Ph.D., ... to provide an overview of the,company, including its clinical ...
Cached Biology Technology:Biodel Inc. Reports Second Quarter Fiscal Year 2008 Financial Results 2Biodel Inc. Reports Second Quarter Fiscal Year 2008 Financial Results 3Biodel Inc. Reports Second Quarter Fiscal Year 2008 Financial Results 4Biodel Inc. Reports Second Quarter Fiscal Year 2008 Financial Results 5Biodel Inc. Reports Second Quarter Fiscal Year 2008 Financial Results 6Biodel Inc. Reports Second Quarter Fiscal Year 2008 Financial Results 7Biodel Inc. Reports Second Quarter Fiscal Year 2008 Financial Results 8Biodel Inc. Reports Second Quarter Fiscal Year 2008 Financial Results 9EUSA Pharma Completes Acquisition Of Cytogen Corporation 2EUSA Pharma Completes Acquisition Of Cytogen Corporation 3Arena Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference 2Arena Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference 3
(Date:10/16/2014)... challenged conventional thinking on how the bowel lining develops ... how bowel cancer starts. , The researchers produced evidence ... the ,crypts, that are a feature of the bowel ... bowel cancer development, a controversial finding as scientists are ... 3D imaging technologies, Dr Chin Wee Tan and Professor ...
(Date:10/16/2014)... Syncytial Virus causes severe respiratory tract infections and ... year. Scientists at VIB and Ghent University have ... counteract this common virus infection. , Xavier ... that paves the way for the development of ... virus that causes suffering in numerous small children ...
(Date:10/16/2014)... , October 16, 2014 NXT-ID, Inc. ... the "Company"), a biometric authentication company focused on the ... leading edge technologies including Wocket™, the Smart Wallet, at ... Conferenece. FiRe is a leading global conference on the ... Hosted by Mark Anderson , founder and publisher ...
Breaking Biology News(10 mins):Cryptic clues drive new theory of bowel cancer development 2New perspectives for development of an RSV vaccine 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3
... In recent years, the possible applications for double-walled ... those working on developing renewable energy technologies. These ... thin enough to be transparent, yet can still ... advanced solar panels, sensors and a host of ...
... for Glycomics in collaboration with colleagues at the ... to identifying a broad spectrum treatment for the ... These highly-infectious viruses are the leading cause of ... of hospitalisations in the developed world, and hundreds ...
... Dec. 23, 2008 -- The reproductive spores of many ... to new research by mycologists and applied mathematicians at ... this week in the Proceedings of the National ... fungal spores is within one percent of the absolute ...
Cached Biology News:Researchers find chink in the armor of viral 'tummy bug' 2In many fungi, reproductive spores are remarkably aerodynamic 2
Porcine Coronary Artery Smooth Muscle Cells (PCASMC) (>500,000 cells)...
... T4 DNA Ligase catalyzes the joining of ... and the 3´-hydroxyl groups of adjacent nucleotides ... (1). The enzyme has also been shown ... either a DNA or RNA strand in ...
... Chain MAP1A and MAP1B are microtubule-associated proteins ... components of the cytoskeleton. MAP1A and MAP1B each ... light chain subunits. The protein encoded by this ... and can associate with either MAP1A or MAP1B. ...
PC based system for advanced chemifluorescent, chemiluminescent, fluorescent and colorimetric, microarray and microscope imaging and analysis....
Biology Products: